Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx

 Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx

Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx

Shots:

  • The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy
  • The Ventana PD-L1 (SP142) assay was used in Roche’s Tecentriq clinical trials to stratify patients and enhances the visual contrast of tumor-infiltrating immune cell staining
  • The Ventana PD-L1 (SP142) assay is a companion diagnostic, performs specific staining of tumor cells with the use of OptiView DAB IHC detection kit with OptiView amplification kit and has received FDA’s Approval for UC & NSCLC with Tecentriq

Click here to read full press release/ article | Ref: Roche | Image: SOM

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post